WO1999011304A1 - Substance filtrante recuperant les leucocytes - Google Patents
Substance filtrante recuperant les leucocytes Download PDFInfo
- Publication number
- WO1999011304A1 WO1999011304A1 PCT/JP1998/003762 JP9803762W WO9911304A1 WO 1999011304 A1 WO1999011304 A1 WO 1999011304A1 JP 9803762 W JP9803762 W JP 9803762W WO 9911304 A1 WO9911304 A1 WO 9911304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- filter material
- hydrophilic
- leukocyte
- group
- leukocyte removal
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 185
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 138
- 210000003743 erythrocyte Anatomy 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 64
- 229920000642 polymer Polymers 0.000 claims description 54
- 239000007788 liquid Substances 0.000 claims description 32
- 239000000178 monomer Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000013626 chemical specie Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 3
- 125000001302 tertiary amino group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 68
- 239000008280 blood Substances 0.000 description 68
- 239000000835 fiber Substances 0.000 description 42
- 238000001914 filtration Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 22
- 239000011148 porous material Substances 0.000 description 18
- 239000004745 nonwoven fabric Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 239000010836 blood and blood product Substances 0.000 description 13
- 229940125691 blood product Drugs 0.000 description 13
- -1 phosphoryl group Chemical group 0.000 description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 102100026735 Coagulation factor VIII Human genes 0.000 description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 7
- 229910052753 mercury Inorganic materials 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- KOAWAWHSMVKCON-UHFFFAOYSA-N 6-[difluoro-(6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(F)(F)C(N1N=2)=NN=C1C=CC=2C1=CC=NC=C1 KOAWAWHSMVKCON-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000012503 blood component Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011045 prefiltration Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- 101150065749 Churc1 gene Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 102100038239 Protein Churchill Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002479 acid--base titration Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000005260 alpha ray Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- WQUVYJNPMXPWQT-UHFFFAOYSA-N (3-amino-2-hydroxypropyl) 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CN WQUVYJNPMXPWQT-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- WYGWHHGCAGTUCH-ISLYRVAYSA-N V-65 Substances CC(C)CC(C)(C#N)\N=N\C(C)(C#N)CC(C)C WYGWHHGCAGTUCH-ISLYRVAYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012784 inorganic fiber Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- FDTHBQVRSIYAPN-UHFFFAOYSA-N n-(2-phenylethenyl)hydroxylamine Chemical compound ONC=CC1=CC=CC=C1 FDTHBQVRSIYAPN-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0088—Physical treatment with compounds, e.g. swelling, coating or impregnation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/08—Filter cloth, i.e. woven, knitted or interlaced material
- B01D39/083—Filter cloth, i.e. woven, knitted or interlaced material of organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/08—Filter cloth, i.e. woven, knitted or interlaced material
- B01D39/086—Filter cloth, i.e. woven, knitted or interlaced material of inorganic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
- B01D67/00931—Chemical modification by introduction of specific groups after membrane formation, e.g. by grafting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0414—Surface modifiers, e.g. comprising ion exchange groups
- B01D2239/0421—Rendering the filter material hydrophilic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0471—Surface coating material
- B01D2239/0478—Surface coating material on a layer of the filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/12—Special parameters characterising the filtering material
- B01D2239/1216—Pore size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/12—Special parameters characterising the filtering material
- B01D2239/1291—Other parameters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/38—Graft polymerization
Definitions
- the present invention relates to a leukocyte removal filter material for removing leukocytes from a leukocyte-containing liquid such as a whole blood product or a concentrated erythrocyte product, and a method for removing leukocytes using the leukocyte removal filter material.
- a blood component required by the recipient from a whole blood product is transfused with blood collected from a blood donor by adding an anticoagulant to the blood.
- component transfusion which separates and injects its blood components, is generally performed.
- Component transfusions include erythrocyte transfusions, platelet transfusions, plasma ring blood, etc., depending on the type of blood component required by the recipient.
- the blood component products used for these transfusions include erythrocyte preparations, platelet preparations , Such as plasma products.
- leukocyte-removal transfusion in which a blood product is transfused after removing leukocytes contained in a blood product, has become widespread.
- These include relatively minor side effects such as headache, nausea, chills, and non-hemolytic fever reactions associated with blood transfusions, and severe effects such as oral antigen sensitization, viral infection, and GVHD after blood transfusion that have a serious effect on recipients. It was clarified that serious side effects were mainly caused by leukocytes contaminating blood products used for transfusion.
- Methods for removing leukocytes from blood products can be broadly divided into centrifugal separators that separate and remove leukocytes using the difference in specific gravity of blood components using a centrifuge, fiber materials, and porous materials with continuous pores.
- Leukocytes using a filter made of porous elements such as porous material
- filters There are two types of filters that remove the noise.
- the filter method has been widely used because it has advantages such as excellent leukocyte removal ability, simple operation, and low cost.
- the method of removing leukocytes by adhesion or adsorption using a nonwoven fabric or a porous material having continuous pores as a filter material is currently most widely used because of its excellent leukocyte removal ability. ing.
- the mechanism of the leukocyte removal using a filter material such as a fiber material or a porous material is mainly based on the fact that leukocytes in contact with the filter material surface are adhered or adsorbed to the filter material surface. Therefore, as a means for improving the leukocyte removal ability of a conventional filter material, the frequency of collision between the filter material and leukocytes is increased, that is, the fiber diameter ⁇ the pore size of the filter material is reduced, Investigations have been conducted to increase the filling density of fill materials in the field.
- JP-A-1 / 249493 discloses a filter material having a hydrophilic and negatively charged surface
- W087 / 055812 discloses a non-ionic hydrophilic group. It discloses a filter material having a basic nitrogen-containing functional group and containing a basic nitrogen-containing functional group in an amount of 0.2% by weight or more and less than 4.0% by weight.
- the above technique aims at maintaining the leukocyte removal ability while improving the passage rate of platelets known as highly adherent cells, and it has been difficult to further improve the leukocyte removal ability.
- JP-A-6 / 247882 has a basic functional group and a nonionic hydrophilic group, and the molar ratio of the basic functional group to the nonionic hydrophilic group is 0.6 or more and less than 6.
- a basic officer The functional group 5 XI 0- 5 meq / m 2 or more 0. Discloses the filters material having a density of less than 1 meq / m 2. However, this filter material was not sufficiently effective in suppressing red blood cell adhesion, and it was difficult to stably improve the ability to remove white blood cells. Disclosure of the invention
- the first object of the present invention is to suppress the adhesion of red blood cells, to have a very high affinity for leukocytes, to provide a leukocyte-removing filter material having a remarkably high leukocyte removal ability, and to have a good flow of a leukocyte-containing liquid, and to be blood compatible.
- An object of the present invention is to provide a leukocyte removal filter material having excellent properties.
- This filter material has a hydrophilic basic group containing at least a nonionic hydrophilic part and a basic part on its surface. In the hydrophilic basic group, the hydrophilic part has the hydrophilic part.
- the present invention relates to a leukocyte-removing filter material for removing leukocytes from a leukocyte-containing liquid, wherein the filter material has a hydrophilic basic group containing at least a nonionic hydrophilic portion and a basic portion on its surface.
- the present invention relates to a leukocyte-removing filter material, wherein the hydrophilic part is located on the terminal side of the basic part in the hydrophilic basic group.
- a second object of the present invention is to provide a method for removing leukocytes from a leukocyte-containing liquid such as a whole blood product or a concentrated erythrocyte product with very high efficiency while suppressing red blood cell adhesion.
- the present inventors inject a leukocyte-containing liquid from the inlet using at least the inlet, a filter appropriately provided with the leukocyte removal filter material of the present invention, and a device including the outlet, and apply the filter through the outlet. It has been found that the above-mentioned second object can be achieved by collecting the liquid filtered by the above method.
- the present invention uses at least 1) an inlet, 2) a filter including the leukocyte-removing filter material according to claim 1, and 3) a device including an outlet, and injects a leukocyte-containing liquid from the inlet.
- a method for removing leukocytes from a leukocyte-containing liquid, comprising recovering the liquid filtered by the filter from an outlet.
- Figure 1 shows the filter material after filtering blood with the leukocyte removal filter material of the present invention.
- 5 is an electron micrograph of the sample.
- Figure 2 is an electron micrograph of the filter material after filtration of the blood, to which a large amount of red blood cells have adhered.
- the leukocyte-removing filter material of the present invention includes a base material for forming a filter material, a hydrophilic basic group on the surface of the base material, and a hydrophilic portion having a more hydrophilic end than a basic portion. It is one filter material located on the side.
- the portion other than the terminal side of the hydrophilic basic group becomes hydrophilic. Even if it has a functional part, it is included in the form of one filter material of the present invention.
- having a hydrophilic basic group on the surface of the base material means that a monomer or polymer containing a hydrophilic basic group has a covalent bond, ionic bond, physical adsorption, embedding, precipitation insolubilization, etc.
- a material is formed, and a hydrophilic basic group is present on the surface of the substrate. Either case is included in the form of the leukocyte removal filter material of the present invention.
- hydrophilic basic group refers to the term “hydrophilic basic group” refers to a portion that retains a hydrophilic basic group (hereinafter also referred to as a “retaining portion”) in a chemical structural formula on the surface of a filter material.
- Distance to the sex part The part at a position longer than the length.
- the holding portion means a portion where the hydrophilic basic group is in contact with the base material forming the filter material.
- a hydrophilic basic group itself or a monomer polymer containing a hydrophilic basic group is introduced into a base material forming a filter material by a covalent bond-ion bond or the like
- the connecting portion with the base material is defined as a holding portion.
- a polymer containing a polymerizable monomer containing a hydrophilic basic group as a constituent component is physically adsorbed onto a surface of a base material forming a filter material by coating or the like, the polymer is removed. Is the main chain.
- the filter material is formed of a polymer material having a hydrophilic basic group as a side chain, a portion where the side chain is bonded to the main chain of the polymer material is used as a holding portion.
- the leukocyte-removing filter material of the present invention is, when the filter material is brought into contact with blood, at a position where the filter material is more easily contacted with blood cells such as red blood cells and white blood cells contained in blood than the basic portion.
- a filter material which does not have a hydrophilic basic group as in the present invention but has a hydrophilic portion and a basic portion independently on its surface, specifically, a dialkylamino group.
- Red blood cell products such as whole blood products and concentrated red blood cell products contain about 100 times the amount of red blood cells as compared to white blood cells. It is probable that the hole was closed and the processing time was extended. It is also probable that red blood cells also adhered to the adsorption seat of the filter material, which should originally adsorb white blood cells, which reduced the ability to remove white blood cells.
- Hydroxyl groups ⁇ represent non-ionic hydrophilic parts such as polyethylene oxide chains. Materials on the surface tend to suppress blood cell adhesion.
- the basic moiety can adsorb cells by electrostatic action due to its positive charge.
- leukocytes tend to stick more easily than erythrocytes, and leukocytes are larger than erythrocytes, so they are more susceptible to electrostatic attraction due to the basic part. It is considered that the part was efficiently and selectively absorbed.
- the filter material of the present invention having a hydrophilic basic group on its surface has an extremely high affinity for leukocytes, and is considered to have an effect of suppressing the desorption of leukocytes once adsorbed on the filter material. This is because, in an experimental system in which erythrocyte adhesion hardly occurs, that is, in which an effect due to erythrocyte adhesion is eliminated, a filter material having a hydrophilic basic group of the present invention on its surface and a basic group such as a dialkylamino group are used. Comparing with the filter material on the surface of the filter, the hydrophilic basic group of the present invention was obtained despite the fact that the introduction density of the hydrophilic basic group and the basic group on the surface of the filter material were almost equal. This can be inferred from the fact that the leukocyte removal ability of the filter material on the surface was significantly higher.
- the present inventors have found the present invention. It is extremely important to introduce a hydrophilic basic group having a specific structure into the surface of the filter material.
- the hydrophilic portion is located at the terminal of the hydrophilic basic group. This is because the effect of further suppressing the attachment of red blood cells tends to be increased by arranging the hydrophilic portion at the extreme end of the hydrophilic basic group.
- the leukocyte-removing filter material of the present invention is also excellent in blood compatibility.
- a nonionic hydrophilic portion such as a hydroxyl group easily induces complement activation, but almost no capturer activation was observed in the leukocyte removal filter material of the present invention.
- the nonionic hydrophilic portion referred to in the present invention refers to a portion having a highly hydrophilic structure that is extremely difficult to ionize. Introducing a non-ionic hydrophilic portion makes the surface of the filter material more likely to get wet when it comes into contact with blood, which has the effect of preventing one-sided flow of blood.As a result, the blood flow area in the filter material increases. It can also contribute to improving the leukocyte removal ability of the filter material.
- nonionic hydrophilic moiety examples include a hydroxyl group, an amide group, an ether group, a nitro group, a nitroso group, a sulfoxide group, a sulfonyl group, a phosphoryl group, a phospho group, a carboxamide, and a sulfonamide.
- a polyethylene oxide chain having a repeating number of ethylene oxide units of 2 or more and 10 or less is preferable as a hydroxyl group, an amide group, or an ether group, which is particularly chemically stable and has high hydrophilicity. Most preferred.
- the basic moiety in the present invention refers to a moiety having a positive charge. Since the basic moiety has a positive charge, it is effective in adsorbing negatively charged leukocytes by electrostatic interaction under physiological conditions, improving the affinity for leukocytes be able to.
- hydrophilic basic group referred to in the present invention is a functional group having a structure containing the above-described nonionic hydrophilic portion and basic portion, and more specifically, the following formula (1) or (2) Means a functional group having a structure represented by Equation U) Equation (2)
- R 2 and R 3 a structure containing a hydrophilic part or a structure without a hydrophilic part such as an alkyl group or hydrogen
- hydrophilic basic groups a monohydroxyalkylamino group, a bis (hydroxyalkyl) amino group, a bis (hydroxyalkyl) amino group in which at least one hydroxyl group is bonded to a positively charged nitrogen atom via a carbon atom.
- a tris (hydroxyalkynole) amino group is preferable, and the number of carbon atoms in the alkyl moiety in the hydroxyalkylamino group structure is preferably 1 or more and 10 or less, more preferably 1 or more and 5 or less.
- the method for introducing the hydrophilic basic group of the present invention to the surface of the substrate on which the filter material is formed there is no particular limitation on the method for introducing the hydrophilic basic group of the present invention to the surface of the substrate on which the filter material is formed, and various known methods can be used.
- a method of introducing a monomer having a hydrophilic basic group by a grafting method such as radiation grafting or plasma grafting a method of coating a polymer having a hydrophilic basic group, or an active group on a substrate surface
- a method of reacting a monomer having a hydrophilic basic group with a chemical species such as a polymer a chemical species such as a polymer.
- Polymerizable monomers having a hydrophilic basic group that can be used in the grafting method or the polymer coating method include N-mono (hydroxyalkyl) aminoethyl (meth) acrylate, N, N-bis (hydroxyalkyl) aminoethyl ( (Meth) acrylate, N-mono (hydroxyalkyl) amino-2-hydroxypropyl (meth) acrylate, N, N-bis (hydroxyalkyl) amino-2-hydroxypropyl (meth) acrylate, N- (methoxypolyoxyethyl) Nore) Aminoethyl (meth) acrylate, N, N-bis (methoxypolyoxyethyl) Rinominethyl (meth) acrylate and other (meth) acrylic acid derivatives, N-hydroxyaminostyrene and other styrene derivatives, N- (hydroxy (Alkyl) amino Vinyl derivatives such as styrene and the like.
- a derivative of (meth) acrylic acid is preferred, and a derivative of (meth) acrylic acid having a mono (hydroxyalkyl) amino group or a bis (hydroquinalkyl) amino group is more preferred.
- the surface of the base material forming the filter material is modified by the grafting method or the polymer coating method, another polymerizable monomer having no hydrophilic basic group may be introduced.
- the other polymerizable monomer is not particularly limited, and any one can be used. However, it is typified by hydroxyethylene (meth) acrylate and methyl (meth) acrylate because of its excellent handleability. Acrylic acid derivatives are preferred.
- the polymer when coating is performed using a polymer having a polymerizable monomer having a hydrophilic basic group and another polymerizable monomer as a component, the polymer may be a random copolymer, a block copolymer, or an alternating copolymer.
- the ability to use any copolymer, such as a polymer ⁇ The random copolymer is more preferred because of the ease of polymerization.
- the type of the polymerizable monomer constituting the above-mentioned copolymer is not particularly limited, but a copolymer composed of two or three types of polymerizable monomers is preferable for reasons such as easy production.
- a substrate having an active group such as an epoxy group, a carboxyl group, or an acid halide on the surface in advance, such as diethanolamine is exemplified.
- a method of introducing a hydrophilic basic group by reacting a chemical species having a hydrophilic basic group such as hydroxyalkylamines may be mentioned.
- a monomer having an active group such as glycidyl (meth) acrylate or (meth) acrylic acid, may be subjected to a radiation grafting method using an ⁇ -ray, an electron beam, or the like.
- the active group is introduced to the surface of the base material by a method such as introducing the active group to the surface of the base material by a method such as synthesizing a polymer having the above-mentioned monomer having an active group as a constituent component, and coating the polymer. Is also good.
- the grafting method and the polymer coating method It is preferable because it is relatively simple, and the polymer coating method is particularly preferable because of its excellent productivity.
- the introduction density of hydrophilic basic groups on the surface of the leukocyte removal filter material of the present invention is
- Introduction density of the hydrophilic basic group 0. 1 ⁇ eq / leukocyte removing capability and m is less than 2 tends you decrease undesirably.
- the cost is undesirably high.
- the introduction density of the hydrophilic basic group on the filter material surface is determined by X-ray photoelectron spectroscopy (XPS), Auger electron spectroscopy (AES), secondary ion mass spectroscopy (SIMS), multiple total reflection Fourier It can be measured by a known method such as conversion infrared spectroscopy (ATR-FTIR).
- XPS X-ray photoelectron spectroscopy
- AES Auger electron spectroscopy
- SIMS secondary ion mass spectroscopy
- ATR-FTIR conversion infrared spectroscopy
- the surface of the filter material is extracted using an appropriate method, and the hydrophilic basic groups contained in the extracted substance are measured using a known method such as a nuclear magnetic resonance spectrum method (NMR). Is also good.
- NMR nuclear magnetic resonance spectrum method
- the introduction density of the hydrophilic basic group may be determined by an acid-base titration / dye adsorption method.
- the dye adsorption method is preferable because the operation is simple.
- the dye adsorption method is a method in which a negatively charged dye such as trypable is adsorbed to a basic portion in a hydrophilic basic group, and the amount of adsorption or change in absorbance changes the hydrophilicity on the filter material surface.
- This is a method for quantifying the amount of a basic group. More specifically, an aqueous solution containing trypan blue and having a pH of about 6 is prepared and used as an original solution. Next, impregnate the filter solution with an appropriate amount of this stock solution and contact it for at least 6 hours at room temperature.
- the sampled filter material was set in a mercury porosimeter (Pore Sizer-1 930 PC2A type Shimadzu Corporation (Japan) or equivalent), and 0.1 to 180
- the surface area (A) is measured in the pressure range of psia, and the surface area per unit weight of the filter material is determined from the following equation (I).
- the ratio of the number of basic parts to the number of nonionic hydrophilic parts is preferably 0.01 or more and less than 0.5. If the number of basic parts relative to the hydrophilic part is less than 0.01, a sufficient effect of improving leukocyte removal may not be obtained, which is not preferable. On the other hand, if the number of basic parts relative to the number of hydrophilic parts exceeds 0.5, it is not preferable because the amount of red blood cells attached tends to increase.
- the number of basic moieties with respect to the number of more preferable hydrophilic moieties is at least 0.03 and less than 0.3.
- the nonionic hydrophilic portion is a polyethylene oxide chain
- the polyethylene oxide chain is not affected by the repeating units of the ethylene oxide chain, that is, regardless of the length of the polyethylene oxide chain.
- the book is considered as one hydrophilic part.
- the base material for forming the filter material in the present invention in addition to nonwoven fabrics manufactured by a melt blowing method, a flash spinning method or a papermaking method, fibers such as paper, woven fabric, and knitted fabric, and porous materials having continuous pores Materials (sponge-like structures) and porous membranes.
- the nonwoven fabric or the porous body is preferable because it has a structure capable of efficiently removing leukocytes.
- the materials include synthetic fibers such as polyamide, polyester, polyacrylonitrile, polytrifluoroethylene, polymethyl methacrylate, polystyrene, polyethylene, and polypropylene.
- Regenerated fiber such as cellulose, purified fiber, cellulose acetate, etc.
- synthetic fibers such as polyester, polypropylene and polyethylene, regenerated fibers such as cellulose, and refined fibers are more preferable from the viewpoints of ease of production and ease of handling.
- the base material when a fiber is used as the base material, the base material may be a base material made of a fiber having a substantially uniform fiber diameter, or may have a fiber diameter as disclosed in WO97Z23326.
- the base material may be a form in which different types of fibers are mixed.
- the fibers preferably have an average fiber diameter of not less than 0.01 and less than 3.0 m. If the average fiber diameter is less than 0.01 m, the mechanical strength of the fiber is low, and there is a possibility that the filter material cannot be manufactured stably, which is not preferable. If the average fiber diameter is 3.0 m or more, the frequency of contact with leukocytes is low, and the effect of the present invention may not be exerted. A more preferable average fiber diameter is 0.1 l / m or more and less than 2.0 m. The average fiber diameter of the fibers referred to here is determined by the following procedure.
- a portion recognized as substantially uniform is sampled and photographed using a scanning electron microscope or the like.
- the material is divided into squares each side of which is about 0.5 cm, and six places are randomly sampled.
- photographs should be taken at three or more locations, preferably at five or more locations, with a magnification of 2000 or more.
- the fiber at the intersection of the vertical and horizontal lines, that is, the fiber at the grid point Measure the width of the fiber in the direction perpendicular to the axis, and use this as the fiber diameter.
- Such measurement is performed on 50 or more fibers, preferably 100 or more fibers, and the average value is defined as the average fiber diameter.
- the average value is defined as the average fiber diameter.
- the material may be polyacrylonitrile, polysulfone, cellulose, cellulose acetate, polyvinyl formal, polyester, poly (meth) acrylate, or polyureta. And the like.
- the average pore diameter of the porous body or the porous membrane is preferably 1 m or more and less than 30 zm. If the average pore diameter is less than 1 zm, the processing time may be prolonged due to the resistance of red blood cells to pass, which is not preferable. If the average pore diameter exceeds 30 m, the frequency of collision with white blood cells decreases, and the effect of the present invention may not be exerted.
- a more preferable average pore diameter is 5 or more and less than 15 m.
- the average pore diameter is a value measured by a mercury intrusion method. In other words, when the mercury intrusion pressure at 0.1 sia is 0.1% and the mercury intrusion pressure at 180 psia is 100%, the mercury intrusion pressure is 50%.
- the corresponding pore diameter is defined as the average pore diameter.
- a second object of the present invention is to provide a method for removing leukocytes from a leukocyte-containing liquid such as a whole blood product or a concentrated erythrocyte product with very high efficiency while suppressing red blood cell adhesion.
- a leukocyte-containing liquid such as a whole blood product or a concentrated erythrocyte product
- the leukocyte-containing liquid was filtered with a device in which at least a container having an inlet and an outlet was appropriately filled with the leukocyte removal filter material of the present invention, and the filtered liquid was filtered. It has been found that the above-mentioned second object can be achieved by collection.
- Examples of the leukocyte-containing liquid to be filtered by a device filled with the leukocyte-removing filter material of the present invention include a whole blood preparation, a concentrated erythrocyte preparation, and a concentrated platelet preparation.
- a device filled with the leukocyte-removing filter material of the present invention By filtering such a leukocyte-containing liquid through a device filled with the leukocyte-removing filter material of the present invention, leukocytes can be efficiently removed, and further, red blood cells such as whole blood products or concentrated red blood cell products can be removed. is against the red cell product containing at X 1 0 9 or concentrations above ZML, also inhibit erythrocyte adhesion of, can give good results.
- red blood cell preparations when a concentrated red blood cell preparation having a plasma protein concentration of 25 gZL or less, or even 10 gZL or less, is filtered using a device filled with the leukocyte removal filter material of the present invention, it is particularly remarkable with respect to suppression of red blood cell adhesion. The effect can be demonstrated.
- the leukocyte-containing liquid is supplied at a rate of 1 gZ min or more and less than 15 g / min. Is preferably filtered.
- an apparatus filled with the leukocyte-removing filter material of the present invention is used to obtain leukocytes from blood products for transfusion at a blood center or the like.
- leukocytes can be removed by using a device filled with the leukocyte removal filter material of the present invention.
- the leukocyte-removing filter material of the present invention has an extremely high affinity for leukocytes and also has an effect of suppressing red blood cell adhesion, it achieves high leukocyte-removing ability and good blood flow. be able to. In addition, since it has extremely excellent blood compatibility, it is possible to ensure ongoing safety as a medical device material.
- Glycidyl methacrylate was added to toluene (purity 9.9% (GC), manufactured by Wako Pure Chemical Industries, Ltd.) to a concentration of 1 mo 1 ZL, and further, 1.1 mol of jetanoamine was added to this solution. The solution was gradually added dropwise so as not to generate heat so that the concentration became 1 ZL, and the total amount was adjusted to 50 OmL. Hydroquinone monomethyl ether (MEHQ) was added as a polymerization inhibitor to a concentration of 0.05 mol 1 ZL, followed by a reaction at 60 ° C for 6 hours.
- MEHQ Hydroquinone monomethyl ether
- HEMA 2-hydroxyethyl methacrylate
- ethanol special grade
- the polymerization conditions were as follows: the concentration of the monomer in ethanol was 1 mo 1 /, and V-65 (manufactured by Wako Pure Chemical Industries, Ltd.) was added as a polymerization initiator to a concentration of 0.0 lmo 1 ZL. Polymerization was carried out at 50 under a nitrogen atmosphere for 4.5 hours.
- the container was packed so that the packing density was about 0.20 g / cm 3 .
- a non-woven fabric with an average fiber diameter of about 1.8 m is placed with a thickness of about 1.5 mm on the blood inlet side, and a non-woven fabric with an average fiber diameter of about 1.2 m with a thickness of about 3.0 mm is placed underneath. Placed.
- An ethanol solution in which HGA-5 polymer was dissolved at a concentration of 0.1% by weight was filled in the container, and the container was allowed to stand for 1 minute. After that, excess liquid was blown off with nitrogen gas, and further vacuum drying was performed at 45 ° C for 16 hours to produce a filter device.
- the leukocyte removal filter material in the prepared filter device had hydrophilic basic groups on its surface at an average introduction density of 1.7 ueq / m 2 .
- CPD solution As an anticoagulant (composition: sodium citrate 26.3 gZL, citrate 3.27 gZL, glucose 23.20 g / L. Phosphorus After centrifugation of 456 mL of whole blood prepared by adding sodium dihydrogen sodium dihydrate (2.5 g / L), the plasma and buffy coat were removed, and 95 mL of red blood cell preservation solution was collected.
- MAP solution Composition: sodium citrate 1.50 g / L, citrate 0.20 g / L. Glucose 7.2 1 g / L.
- a nonwoven fabric with a fiber diameter of about 33 3m is placed at a thickness of about 1.2 mm, and a nonwoven fabric with an average fiber diameter of about 12 zm is placed at a thickness of about 2.3 mm, and the packing density is about 0.25 g / cm It filtered using the filter 1 made into 3 .
- 32.5 g of the concentrated erythrocyte preparation from which microaggregates had been removed was allowed to stand at room temperature of 24 ° C., and filtered through a lm head using a filter coated with HGA-5.
- the filter was connected to the blood bag containing the concentrated red blood cell product via a blood circuit, and the blood bag was grasped by hand and pressurized to forcibly fill the filter with blood. .
- the blood Filtration was performed until no blood remained in the bag, and the filtered blood was collected.
- the filtration time at this time was from the time when blood began to flow out of the outlet of the filter to the time when blood in the blood bag was exhausted.
- the leukocyte concentration of the concentrated red blood cell preparation before filtration (hereinafter referred to as pre-filtration liquid) and the recovered concentrated red blood cell preparation (hereinafter referred to as recovery liquid), the volume of the pre-filtration liquid and the volume of the recovered liquid
- the leukocyte removal ability was determined according to the following formula (II).
- Leukocyte removal ability 1 Lo g ⁇ (white blood cell concentration in recovered liquid x volume of recovered liquid) / (white blood cell concentration in pre-filtration liquid x volume of pre-filtration liquid)) ( ⁇ ) Each weight was divided by the specific gravity (1.075) of the blood product.
- the leukocyte concentration of the pre-filtration solution was measured by diluting it 10-fold with Turk's solution, injecting it into a Burger-Turk type hemocytometer, and counting the number of leukocytes using an optical microscope.
- the leukocyte concentration of the recovered solution was measured by the following method. Recovered solution is used as Reyuko plate solution
- the filtration time was 10.4 minutes, and the leukocyte removal ability was 4.45.
- the filter material after blood filtration was sufficiently washed with physiological saline, fixed with 0.2% glutaraldehyde, and further freeze-dried. Observation with a scanning electron microscope of the filter material after filtration of the blood subjected to such pretreatment showed that red blood cells were hardly adhered.
- Example 2 a polymer containing about 25 mol% of a GA component (hereinafter referred to as HGA-25) was obtained and coated on a filter in the same manner as in Example 1. Operations were performed in the same manner as in Example 1 except for the above.
- the average introduction density of the hydrophilic basic group to the surface of the filter material is 7. a 3 neq / m 2, the time taken to you filtered blood 1 0.2 min, leukocyte removal performance in 5.24 there were. Also blood Almost no erythrocytes were attached to the filter material after filtration.
- Example 2 a polymer containing about 4 Omo 1% of a GA component (hereinafter referred to as HGA-40) was obtained, and coated on a filter in the same manner as in Example 1. Other than that, operation was performed in the same manner as in Example 1.
- the average introduction density of the hydrophilic basic group to the surface of the filter material is 1 0.
- Q ⁇ q / m 2 blood 1 0.9 minute time required for filtering the leukocyte removing capability is 5.1 was 2. Also, almost no erythrocytes were attached to the filter material after blood filtration.
- Example 2 By the same synthesis method as in Example 1, a polymer containing about 7 Omo 1% of GA component (hereinafter referred to as 1 ⁇ 0-70) was obtained. Operations were performed in the same manner as in Example 1 except that coating was performed.
- the average introduction density of the hydrophilic basic group to the filter one substrate surface is 1 5. 4 eq / m 2, blood 1 1.5 minute time required for filtering the leukocyte removing capability is 4.9 Was 3. Further, almost no red blood cells were attached to the filter material after the blood filtration.
- Example 1 By the same polymerization method as in Example 1, a polymer composed of N, N-getylaminoethyl methacrylate (hereinafter, referred to as DE) and HEMA was synthesized.
- DE N, N-getylaminoethyl methacrylate
- HEMA HEMA
- Example 1 was repeated except that this polymer was coated on a filter in the same manner as in Example 1. The same operation was performed.
- the average introduction density of basic groups (diethylamino groups) on the surface of one filter material is 1.8 ⁇ eq / m 2 , the time required to filter blood is 11.3 minutes, and the leukocyte removal ability is 3.41. Also, almost no red blood cells were attached to one filter material after the blood filtration.
- a polymer containing about 25 mo 1% of DE (hereinafter referred to as HDE-25) was obtained by the same polymerization method as in Comparative Example 1, except that the polymer was coated on the filter in the same manner as in Example 1. The operation was performed in the same manner as in Example 1.
- the average introduction density of basic groups on the surface of the filter material is 8. 1 eq / m 2, when taken to filter blood The interval was 35.7 minutes, and the leukocyte removal ability was 2.84. It was also observed that red blood cells had adhered to the filter material after blood filtration.
- a polymer containing about 4 Omo 1% of DE (hereinafter referred to as HDE-40) was obtained by the same polymerization method as in Comparative Example 1, and was coated on a filter in the same manner as in Example 1. The same operation as in 1 was performed.
- the average introduction density of basic groups on the surface of the filter material is 1 2.
- a 3 eq / m 2 the time required to filter blood 6 2.3 min, leukocyte removal capacity 2.9 0 met was.
- DP N, N-getylamino-2-hydroxypropyl methacrylate
- HEMA HEMA
- the DP content in the obtained polymer was about 4 Omo 1% (hereinafter, this polymer is referred to as HDP-40), and the polymer was coated in the same manner as in Example 1 except that this polymer was coated.
- the same operation as in 1 was performed.
- a hydrophilic basic group having no hydrophilic portion at the end was introduced into the surface of the filter material at an average introduction density of 12.0 pi eq / m 2 .
- the time required to filter the blood was 54.5 minutes and the leukocyte removal capacity was 2.73. It was also observed that a large amount of red blood cells had adhered to one filter material after blood filtration.
- Example 1 Using the same filter 1 as in Example 1 except that the polymer was not coated, the concentrated red blood cell preparation was filtered in the same manner as in Example 1. As a result, the blood filtration time was 12.2 minutes, and the leukocyte removal ability was 3.23. Erythrocytes hardly adhered to the filter material after hemofiltration. Table 1 collectively shows the results of Examples 1 to 4 and Comparative Examples 1 to 5.
- GM and GM N-methyl-N-hydroxyquinethyl amino-2-hydroxypropyl methacrylate
- Example 2 By the same polymerization method as in Example 1, a polymer composed of GM and HEMA was synthesized.
- the GM content in the obtained polymer was about 25 mol% (hereinafter, this polymer is referred to as HGMA-25), and the polymer was coated on a filter in the same manner as in Example 1.
- the operation was performed in the same manner as in Example 1.
- the average introduction density of the hydrophilic basic group to the filter material table surface (N- methyl -N- hydroxy E chill ⁇ amino group) is 7. 7 e QZm 2, the time required to filter blood At 1.1.8 minutes, the leukocyte removal capacity was 4.54. Also, almost no red blood cells were attached to the filter material after blood filtration.
- Example 2 By the same polymerization method as in Example 1, GA, HEMA and methyl methacrylate (Hereinafter referred to as MMA) was synthesized.
- the obtained polymer contained about 20 mo 1% GA and about 4 Omo 1% each of HEMA and MMA by acid-base titration, nuclear magnetic resonance spectrum (NMR) and elemental analysis (hereinafter, this The polymer is called HMG A-20).
- the same operation as in Example 1 was performed except that the polymer was coated on a filter in the same manner as in Example 1.
- Example 8 By the same polymerization method as in Example 1, a polymer composed of EA and HEMA was synthesized.
- the EA content of the obtained polymer was about 25 mo 1% (hereinafter, this polymer is referred to as HEA-25), and this polymer was coated on a filter in the same manner as in Example 1. Other than that, operation was performed in the same manner as in Example 1.
- the average introduction density of the hydrophilic basic group to the surface of the filter material is 6. 3 eq / m z, time required for you filtered blood 1 2.1 min, leukocyte removal performance in 4.07 there were. Also, almost no red blood cells were attached to the filter material after blood filtration.
- Example 8 Example 8
- a polyester nonwoven fabric (5 g) having an average fiber diameter of 1.2 m was immersed in 6 mL of a 10% aqueous solution of tertiary butyl alcohol containing methacrylic acid (30 OmL). By irradiating this sample solution with a line of about 1 kGy, methacrylic acid was graft-polymerized on the surface of the nonwoven fabric.
- the non-woven fabric irradiated with the ⁇ -ray was washed by shaking with methanol at room temperature for 10 minutes, and further washed by shaking with warm water at 40 ° C for 2 hours.
- the nonwoven fabric graft-polymerized with chloroform solution containing triethanolamine at a concentration of 0.02mo 1ZL is immersed, and sulfuric acid is added for 6 hours. Heated to reflux.
- esterification occurs between the carboxyl group on the surface of the nonwoven fabric and the hydroxyl group of triethanolamine, thereby removing leukocytes having a hydrophilic basic group (bis (hydroxyethyl) amino group) on the surface.
- Filter material was prepared. The density of introduction of hydrophilic basic groups onto the surface of one filter was 6.9 eq / m '.
- the obtained filter material was filled into a container having an effective filtration cross-sectional area of 67 mm ⁇ 67 mm so as to have a thickness of 3.0 mm and a packing density of 0.20 g / cm 3 .
- a filter device was prepared in which the upper layer was filled with non-grafted nonwoven fabric having an average fiber diameter of 1.8 ⁇ m and a thickness of 1.5 mm.
- a nonwoven polyester fabric having an average fiber diameter of 8 m and 1.2 ⁇ m as in Example 1 was placed in a container having an effective filtration area of 67 mm x 67 mm and a packing density of 0.24 g / Filled to give cm 3 .
- a nonwoven fabric with an average fiber diameter of 1.8 ⁇ m is placed on the blood inlet side with a thickness of 0.5 mm, and a nonwoven fabric with an average fiber diameter of 1.2 ⁇ m is placed below it with a thickness of 4.7 mm. did.
- a 0.5% by weight ethanol solution of HGA-25 polymer was filled in this container and allowed to stand for 1 minute. After that, excess liquid is blown off with nitrogen gas and vacuum dried at 45 ° C for 16 hours.
- the leukocyte removal filter material in the filter device thus prepared had hydrophilic basic groups on its surface at an average introduction density of 16.8 // eq / m 2 .
- Microaggregates contained in CPD-added human neonatal whole blood (hematocrit 39%) stored at room temperature for 16 hours after blood collection were removed in the same manner as in Example 1. Thereafter, using the prepared filter device, 5 15 g of human whole blood was filtered with a head of 0.7 m. The temperature of fresh human whole blood with CPD immediately before starting filtration was 25 ° C. In addition to measuring the blood filtration time and leukocyte removal ability, the concentration of C3a as an activated complement and the amount of blood coagulation factor Factor VI were measured.
- Example 9 The same filter device as in Example 9 was coated with a 0.5% by weight ethanol solution of HDE-25 polymer, and the human whole fresh blood with CPD was filtered in the same manner as in Example 9.
- the average introduction density of basic groups on the filter material surface was 18.6 fieq / m 2 .
- the filtration time was 24.5 minutes and the leukocyte removal ability was 3.73.
- the concentration of C 3 a in the recovered liquid was about twice as high as that before filtration, and the amount of factor ⁇ 1 was reduced by about 30%.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002301726A CA2301726C (en) | 1997-08-28 | 1998-08-25 | Leucocyte-removing filter medium |
EP98938975A EP1016426B1 (en) | 1997-08-28 | 1998-08-25 | Leukocyte-removing filter material |
DE69834651T DE69834651T2 (de) | 1997-08-28 | 1998-08-25 | Filtermaterial zur entfernung von weissen blutkörperchen |
US09/485,668 US6352642B1 (en) | 1997-08-28 | 1998-08-25 | Leukocyte-removing filter material |
JP51657199A JP4271265B2 (ja) | 1997-08-28 | 1998-08-25 | 白血球除去フィルター材 |
KR1020007001987A KR100343092B1 (ko) | 1997-08-28 | 1998-08-25 | 백혈구-제거용 여과재 |
AU87504/98A AU726974B2 (en) | 1997-08-28 | 1998-08-25 | Leucocyte-removing filter medium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/247812 | 1997-08-28 | ||
JP24781297 | 1997-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999011304A1 true WO1999011304A1 (fr) | 1999-03-11 |
Family
ID=17169039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003762 WO1999011304A1 (fr) | 1997-08-28 | 1998-08-25 | Substance filtrante recuperant les leucocytes |
Country Status (10)
Country | Link |
---|---|
US (1) | US6352642B1 (ja) |
EP (1) | EP1016426B1 (ja) |
JP (1) | JP4271265B2 (ja) |
KR (1) | KR100343092B1 (ja) |
CN (1) | CN1177620C (ja) |
AT (1) | ATE326990T1 (ja) |
AU (1) | AU726974B2 (ja) |
CA (1) | CA2301726C (ja) |
DE (1) | DE69834651T2 (ja) |
WO (1) | WO1999011304A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002161048A (ja) * | 2000-11-24 | 2002-06-04 | Terumo Corp | 血小板放出因子調製用フィルター及び血小板放出因子の調製方法 |
JP2004529076A (ja) * | 2000-12-05 | 2004-09-24 | ハーベスト・テクノロジーズ・コーポレイション | 赤血球の沈殿方法 |
CN100342927C (zh) * | 1999-11-01 | 2007-10-17 | 旭化成医疗株式会社 | 用于选择性去除白血球的过滤器 |
US7721898B2 (en) | 2001-07-31 | 2010-05-25 | Asahi Kasei Medical Co., Ltd. | Coating material for leukocyte removal filter and the filter |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410066B2 (en) * | 2001-12-03 | 2008-08-12 | Ashai Kasei Medical Co., Ltd | Filter for selectively eliminating leukocytes |
US7439013B2 (en) * | 2002-06-17 | 2008-10-21 | Asahi Kasei Kuraray Medical Co., Ltd. | Biocompatible polymer and filter for selectively eliminating leucocytes using the same |
US7592134B2 (en) | 2002-10-16 | 2009-09-22 | Asahi Kasei Medical Co., Ltd. | Viral reduction method for plasma using a leukocyte-reduction filter and two virus-reduction filters of decreasing pore diameters |
CN101862564B (zh) * | 2010-03-16 | 2012-03-21 | 苏州市玮琪生物科技有限公司 | 一种微量血样预处理系统及其制备工艺 |
TWI410269B (zh) * | 2010-09-16 | 2013-10-01 | 私立中原大學 | 白血球過濾材料及其過濾方法 |
EP2495025A1 (en) * | 2011-03-04 | 2012-09-05 | Fresenius Medical Care Deutschland GmbH | Filter for the removal of micro-vesicles from biological fluids, methods and devices using such a filter |
US20140234506A1 (en) * | 2013-02-18 | 2014-08-21 | Wisconsin Alumni Research Foundation | Methods and compositions for protein concentration |
EP3006058B1 (en) * | 2013-06-07 | 2021-11-10 | Nissan Chemical Corporation | Blood filter and method for producing same |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
WO2016030357A1 (de) | 2014-08-26 | 2016-03-03 | 3M Innovative Properties Company | System zur entfernung von proinflammatorischen mediatoren sowie von granulozyten und monozyten aus blut |
CN106117590A (zh) * | 2016-06-22 | 2016-11-16 | 广州新克力生物科技有限公司 | 一种白细胞过滤膜的改性方法 |
CN106117580A (zh) * | 2016-06-23 | 2016-11-16 | 广州新克力生物科技有限公司 | 一种用于滤除白细胞的滤膜改性剂及其改性方法 |
ES2845176T3 (es) * | 2016-08-18 | 2021-07-26 | Asahi Kasei Medical Co Ltd | Elemento de filtro para filtro de tratamiento de sangre, filtro de tratamiento de sangre y método de retirada de leucocitos |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005812A1 (en) * | 1986-03-28 | 1987-10-08 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
JPH06247862A (ja) * | 1992-12-28 | 1994-09-06 | Asahi Medical Co Ltd | 白血球除去フィルター材料、白血球除去装置および白血球除去方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711793A (en) * | 1980-10-27 | 1987-12-08 | Cuno Incorporated | Process for charge modifying a microphorous membrane |
CA1335713C (en) | 1988-02-17 | 1995-05-30 | David Boris Pall | Device and method for separating leucocytes from platelet concentrate |
CA1329559C (en) * | 1988-03-03 | 1994-05-17 | Keiji Naoi | Leukocyte separator and method of making the same |
US5344561A (en) * | 1989-05-09 | 1994-09-06 | Pall Corporation | Device for depletion of the leucocyte content of blood and blood components |
US5217627A (en) * | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
JP3124565B2 (ja) | 1991-02-22 | 2001-01-15 | テルモ株式会社 | 白血球除去フィルターおよび白血球除去装置 |
US5498336A (en) * | 1991-02-22 | 1996-03-12 | Terumo Kabushiki Kaisha | Leukocyte-removing filter and leukocyte-removing apparatus furnished therewith |
US5407581A (en) * | 1992-03-17 | 1995-04-18 | Asahi Medical Co., Ltd. | Filter medium having a limited surface negative charge for treating a blood material |
DE69327891T2 (de) * | 1992-07-06 | 2000-07-20 | Terumo Corp | Material zur Entfernung von pathogener Substanz und mit diesem Material hergestellter Blutfilter |
EP0606646B1 (en) | 1992-12-28 | 1997-09-24 | Asahi Medical Co., Ltd. | Filtermaterial, apparatus and method for removing leukocytes |
JP2000515062A (ja) * | 1996-07-08 | 2000-11-14 | ユーエスエフ フィルトレイション アンド セパレーションズ グループ インコーポレイテッド | カチオン電荷修飾されたメンブレン |
-
1998
- 1998-08-25 DE DE69834651T patent/DE69834651T2/de not_active Expired - Fee Related
- 1998-08-25 US US09/485,668 patent/US6352642B1/en not_active Expired - Lifetime
- 1998-08-25 WO PCT/JP1998/003762 patent/WO1999011304A1/ja active IP Right Grant
- 1998-08-25 CN CNB988086131A patent/CN1177620C/zh not_active Expired - Fee Related
- 1998-08-25 EP EP98938975A patent/EP1016426B1/en not_active Expired - Lifetime
- 1998-08-25 KR KR1020007001987A patent/KR100343092B1/ko not_active IP Right Cessation
- 1998-08-25 CA CA002301726A patent/CA2301726C/en not_active Expired - Fee Related
- 1998-08-25 AT AT98938975T patent/ATE326990T1/de not_active IP Right Cessation
- 1998-08-25 JP JP51657199A patent/JP4271265B2/ja not_active Expired - Fee Related
- 1998-08-25 AU AU87504/98A patent/AU726974B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005812A1 (en) * | 1986-03-28 | 1987-10-08 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
JPH06247862A (ja) * | 1992-12-28 | 1994-09-06 | Asahi Medical Co Ltd | 白血球除去フィルター材料、白血球除去装置および白血球除去方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100342927C (zh) * | 1999-11-01 | 2007-10-17 | 旭化成医疗株式会社 | 用于选择性去除白血球的过滤器 |
JP2002161048A (ja) * | 2000-11-24 | 2002-06-04 | Terumo Corp | 血小板放出因子調製用フィルター及び血小板放出因子の調製方法 |
JP2004529076A (ja) * | 2000-12-05 | 2004-09-24 | ハーベスト・テクノロジーズ・コーポレイション | 赤血球の沈殿方法 |
US7721898B2 (en) | 2001-07-31 | 2010-05-25 | Asahi Kasei Medical Co., Ltd. | Coating material for leukocyte removal filter and the filter |
Also Published As
Publication number | Publication date |
---|---|
KR20010023349A (ko) | 2001-03-26 |
DE69834651D1 (de) | 2006-06-29 |
AU726974B2 (en) | 2000-11-30 |
ATE326990T1 (de) | 2006-06-15 |
CA2301726A1 (en) | 1999-03-11 |
EP1016426B1 (en) | 2006-05-24 |
EP1016426A4 (en) | 2001-08-22 |
JP4271265B2 (ja) | 2009-06-03 |
DE69834651T2 (de) | 2007-04-26 |
CN1268893A (zh) | 2000-10-04 |
KR100343092B1 (ko) | 2002-07-05 |
CA2301726C (en) | 2003-06-10 |
CN1177620C (zh) | 2004-12-01 |
EP1016426A1 (en) | 2000-07-05 |
US6352642B1 (en) | 2002-03-05 |
AU8750498A (en) | 1999-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4271265B2 (ja) | 白血球除去フィルター材 | |
JP4587213B2 (ja) | 生体適合性ポリマーおよびそれを用いた白血球選択除去フィルター材 | |
CA2455786C (en) | Coating material for leukocyte removal filter and the filter | |
JP3461360B2 (ja) | 白血球除去用フィルター材料 | |
WO2002060557A1 (fr) | Filtre destine au traitement du sang et procede de production d'un tel filtre | |
JP3741320B2 (ja) | 白血球選択除去フィルター材 | |
JP3176752B2 (ja) | 血液濾過材 | |
WO2003047655A1 (fr) | Filtre pour l'elimination selective de leucocytes | |
JP3270125B2 (ja) | 白血球捕捉材 | |
JP3534361B2 (ja) | 白血球除去材料 | |
JP3250833B2 (ja) | 白血球選択捕捉フィルター材料 | |
JP3459836B2 (ja) | 血小板純化用フィルター | |
JP4148309B2 (ja) | 微小凝集物除去フィルター材 | |
JP2006077136A (ja) | 生体適合性ポリマーの製造方法 | |
JP4393218B2 (ja) | ウイルス除去用血液処理装置およびウイルス除去方法 | |
JP3379972B2 (ja) | 白血球捕捉体およびその製造方法 | |
JP4082894B2 (ja) | 白血球選択除去フィルター材 | |
JP2000245833A (ja) | 白血球選択除去材 | |
JP4082893B2 (ja) | 耐滅菌性に優れた白血球選択除去フィルター材 | |
JP2001300221A (ja) | 白血球除去用フィルター材及び該フィルター用ポリマー | |
KR100229579B1 (ko) | 개질 키토산으로 도포된 백혈구 제거용 필터 | |
JP2001137337A (ja) | 白血球選択除去フィルター |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808613.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998938975 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09485668 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2301726 Country of ref document: CA Ref document number: 2301726 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 87504/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007001987 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938975 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 87504/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007001987 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007001987 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998938975 Country of ref document: EP |